To evaluate the impact of long-term outcomes of transarterial embolization (TAE) therapy in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) on the waiting list for liver transplantation (LT).
A lthough the incidence of most forms of cancers are declining, hepatocellular carcinoma (HCC) continues to rise and claims over half a million lives world-wide each year. 1, 2 This increase is largely related to the current epidemic of hepatitis C virus (HCV) infection. 3 Furthermore, the increases in obesity and diabetes have also been identified as independent risk factors for chronic liver disease and HCC. 4, 5 Even though the majority of patients lack a viable option for long-term cure because of extensive tumor burden on presentation, a small group of patients presenting with early HCC can achieve long-term survival with liver transplantation (LT). LT offers the unique ability to address both disease processes that coexist in the patients by replacing the oncogenic cirrhotic liver and removing the HCC. Unfortunately, the shortage of available donor liver organs has forced the development of the Milan criteria for liver allocation in HCC. The Milan criteria are defined as HCC confined to the liver with a single tumor < 5 cm or 3 nodules < 3 cm with no evidence of vascular invasion. 6 When LT for HCC is restricted to patients meeting the Milan criteria, the long-term post-LT survival is comparable with nonmalignant conditions (70% survival at 5 y). In addition, the rate of tumor recurrence is minimized. The United Network for Organ Sharing applies the Milan criteria for patients undergoing LT for HCC by awarding priority points to this subset of patients. The priority points increase the likelihood patients with HCC receive an LT. Once patients are listed for LT, the majority of transplant centers choose to treat the HCC to reduce the tumor burden and delay tumor progression.
The management of early stage HCC in the background of cirrhosis is a clinical challenge particularly once patients are listed. Although wide agreement on using LT for HCC within the Milan criteria exists, the management strategies for this group of patients is increasingly complex because of concerns of dropout from the waiting list, shortage of liver organs, and the various options available to treat while on the waiting list. Upon enlistment, patients remain at risk of dropout and dying on the list from tumor progression pressing treatment of the tumor as this may delay progression and reduce risk of exclusion. Transarterial therapy such as chemoembolization (TACE) is an ideal treatment for patients with HCC on the waiting list given its already proven efficacy and acceptable safety profile as a palliative treatment. In patients with preserved liver function and large or multifocal HCC without vascular invasion or extrahepatic spread representing the intermediate HCC subset category within the Barcelona Clinic Liver Cancer staging system, TACE is the preferred treatment option. 7 TACE as a neoadjuvant therapy in the pre-LT setting for patients with HCC is an attractive strategy to locally control the tumor to keep patients within the Milan criteria and translate into acceptable post-LT survival with minimal recurrence. The impact of transarterial therapy in the form of TACE or bland embolization [transarterial embolization (TAE)] on tumor recurrence and post-LT patient survival for those with HCC within the Milan criteria remains to be adequately prospectively validated. However, a strategy of observation for patients with HCC that are on the waiting list places them at considerable risk of dropout because of tumor progression and thus unlikely to be a control arm of future prospective clinical studies.
Controlled prospective studies are also a challenge, as the technique of transarterial therapy is performed in a heterogeneous manner across transplant centers. However, the most important part of the transarterial technique is the embolization component that results in acute arterial occlusion and induces ischemic tumor necrosis. Our institutional practice during a 10-year period included using TAE in patients with HCV-related HCC upon listing for LT. In this study, we carry out a retrospective cohort analysis during this period to evaluate the impact of transarterial therapy on long-term outcomes of patients with HCV-related HCC after LT. Here, we report the post-LT survival of a uniform population of patients with regards to underlying liver disease (HCV-related HCC) and tumor burden (Milan criteria) that received pre-LT transarterial therapy (PTT) once listed and compare them with those who had no pre-LT transarterial treatment (NTT).
MATERIALS AND METHODS

Patients
In this retrospective analysis, patients with HCV-related HCC who underwent LT at the University of Florida between 1996 and 2005 represented the study cohort (n = 80). Patients were excluded from the study if they had any other liver disease (eg, alcoholic liver disease, hepatitis B, nonalcoholic fatty liver disease, autoimmune hepatitis, genetic diseases). All the study patients had tumor burden within Milan criteria. 6 HCC was diagnosed using the American Association for the Study of Liver Diseases HCC management guidelines. 8 The protocol was approved by the Institutional Review Board at University of Florida.
Data Collection
The following data were collected for all patients: (1) demographics---age, sex, ethnicity; (2) tumor-related data---size and number of lesions in pretransplant imaging, occurrence of recurrence after LT; (3) pathologic features on explants-grade of tumor, degree of differentiations, and microvascular invasion; (4) laboratory parameters including liver function tests, creatinine, and serum a-fetoprotein before transplant; (5) transplant data-date of listing and date of transplant, warm and cold ischemic times; (6) details of pre-LT transarterial therpay; and (7) HCV-related data---interferon therapy before transplant, recurrence of HCV in the transplanted liver, stage of fibrosis in post-LT protocol liver biopsies.
Histopathology
Protocol liver biopsies in HCV recipients were performed at 4 months post LT and then annually. Liver biopsies were reviewed and staged by 2 experienced liver pathologists. A Modified Knodell scoring system of Ishak et al 9 system was used to score inflammation and fibrosis. Patients with stage of fibrosis Z2 at year 2 post transplantation were referred to as rapid fibrosers, whereas the remainders were referred to as slow fibrosers. 10 
Transarterial Treatment and Tumor Response Monitoring
Transcatheter therapy in the form of TAE was performed in the Department of Interventional Radiology. TAE consisted of the administration of a combination of Ethiodol (Savage Laboratories, Melville, NY) and embolic particles, initially polyvinyl alcohol followed later by Embospheres (Biosphere Medical, Rockland, MA) 500 to 700 m until the feeding arterial supply to the tumor was static. The number of treatments administered was delivered based on tumor burden and underlying liver disease. Feeding vessels were taken to near stasis. Dynamic imaging with a 4-phase computed tomography was performed 1 month after TAE treatment. Residual tumor and the extent of tumor necrosis were evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines and the modified Response Evaluation Criteria in Solid Tumors criteria. 11 Further treatment was decided by consensus in a multidisciplinary HCC conference after review of follow-up images to characterize the tumor response.
Study End Points
The study cohort of patients with HCV-related HCC within the Milan criteria was divided into patients who received PTT (PTT group; n = 33) and those who had NTT (NTT group; n = 47) to determine the impact of TAE on the post-LT survival rates. Demographic, tumor-related, transplant-related, and HCV-related factors were evaluated to identify predictors of posttransplant survival.
Statistical Analysis
The w 2 test was used to compare categorical variables and student t tests were used to compare continuous variables. Survival time was defined as the time from the time of transplant to the date of death or the date of last follow-up. Survival analysis was carried out using Kaplan-Meier Estimator method. In univariate analysis, survival estimates were compared with log rank test in the Kaplan-Meier Estimator method. Multivariate analysis was carried out using the Cox proportional hazards with the backward Wald method. Only variables found to be significant on univariate analysis were included in multivariate analysis. The SPSS Graduate version 16.0 (SPSS Inc., Chicago, IL) was used for all statistical computations.
RESULTS
Study Cohort
During the study period, of the 424 patients who received an LT for HCV-related liver disease, 80 patients (18.8%) carried a diagnosis of HCC before LT ( Table 1 ). The mean age of the study cohort was 58.7 years (range, 42 to 73 y); 82.5% (66 of 80) were male patients and 81.2% (65 of 80) were White patients. All patients had tumor burden within Milan criteria; 58.8% (47 of 80) had a single tumor and 41.2% (33 of 80) had 2 to 3 tumors. The mean duration of posttransplant follow-up of the patients was 3.5 years (range, 0.01 to 11.4 y). The mean time spent on transplant waiting list in the study cohort was 120 days (range, 1 to 592 d). The time from listing to transplant in the pre-Model of End Stage Liver Disease era (before February 2002) was 167 days and in the post-Model of End Stage Liver Disease era was 84 days (P = 0.017). A total of 34 patients (42.5%) died in the posttransplant period. For the study cohort, the most common cause of death was recurrence of HCC ( Table 2 ). The median posttransplant survival in the study cohort was 8.9 years [95% confidence interval (CI), 3.7-14.2]. The survival rate at 1 year was 82%, at 3 years was 70%, at 5 years was 55%, and at 10 years was 35%.
Study Groups (PTT vs. NTT)
Within the study cohort of patients with HCV-related HCC, 58.7% of the patients (47 of 80) did not receive transarterial treatment (NTT group), whereas 41.3% of the patients (33 of 80) underwent bland embolization (PTT group) before transplantation. The 2 study groups (PTT vs. NTT) are well matched for the majority of demographic variables, tumor-related factors, and histologic features of the HCC on the explant (Table 3 ). The HCC recurrence rate was 15.6% in the PTT group and 6.9% in the NTT group (P = 0.275). The waiting time on the list was significantly shorter for the PTT (mean, 56.2 d) versus NTT group (164.6 d, P < 0.001). In addition to the waiting time, the NTT patients were more likely to receive post-LT interferon-based treatment in comparison with the PTT patients for recurrence of HCV in the liver allograft.
Post-LT Survival for PTT Versus NTT Patients
The median survival in the NTT group was longer (8.9 y, 95% CI, 3.3-14.5) than the PTT group (4.8 y, 95% CI, 2.7-6.9) but this difference was not statistically significant (P = 0.148) (Fig. 1) . Although the survival rates at 1 and 3 years were similar, the survival rate at 5 years was significantly better among patients who did not receive PTT (Fig. 2) .
Prognostic Factors
To determine which variables can predict posttransplant survival, several prognostic factors were evaluated by univariate analysis for the full study cohort of 80 patients ( Table 4 ). The age and race of the patient did not influence survival, but sex was a significant prognostic factor. The median survival in male patients was 8.9 years (95% CI, 3.3-14.5), whereas in female patients it was 3.8 years (95% CI, 0.1-8.1, P = 0.047). The incidence of HCC recurrence was 10.6% with 5 patients lost to follow-up. In patients who developed HCC recurrence, the median survival was 1.3 years (95% CI, 0.5-2.1). In contrast, the patients without tumor recurrence had a significantly longer median survival of 8.9 years (95% CI, 2.3-15.9; P = 0.001).
The presence of microvascular invasion was observed in 18.8% of the liver explants on histopathology. In patients whose tumors showed microvascular invasion, the posttransplant survival was 3.4 years (range, 2.7 to 4.0 y), whereas in patients without microvascular invasion it was 5.4 years (95% CI, 2.6-8.2; P = 0.398). The incidence of recurrence was significantly higher in patients with microvascular invasion (33%) than in patients who did not have microvascular invasion (5%; P = 0.008). In addition, tumor focality, serum a-fetoprotein class, tumor differentiation on explant histopathology, and rate of fibrosis progression did not influence posttransplant survival.
On multivariate analysis of prognostic factors, sex and recurrence of HCC were included in the model as they were the only 2 factors found significant on univariate analysis (Table 4) . Both factors were found to independently and significantly influence posttransplant survival among HCV-related HCC patients, sex [hazard ratio 2.3 (95% CI, 1.0-5.4); P = 0.05], and recurrence of HCC [hazard ratio 5.0 (95% CI, 2.1-11.7); P < 0.001].
DISCUSSION
Our study shows that once patients with HCV-related HCC are listed for LT, PTT in the form of bland embolization has no benefit on either post-LT survival or tumor recurrence. The failure of TAE to impact patient survival after LT for HCC has also been reported by others. In a multicenter case-control study, pre-LT TACE did not influence post-LT overall survival and disease-free survival. 12 Even after adjusting for patients with tumor burden beyond the Milan criteria, the overall survival rates remained similar in the TACE versus no TACE patient subgroups. In a second retrospective study, TACE before LT failed to result in a significant improvement in survival. 13 In this second study, the majority of the patients had preserved liver function with HCV infection as the underlying etiology similar to our study. These and other retrospective studies corroborate our findings that TACE treated patients lack a survival benefit, despite TACE inducing marked tumor necrosis. 14 Most studies that suggest a benefit of TACE in patients awaiting LT have been cohort studies without a control group. For example, 1 prospective study of 48 patients reported an intention-to-treat survival >90% at 5 years for patients with HCC within the Milan criteria. 15 Further, none of the patients dropped off the waiting list because of tumor progression when receiving TACE after a mean waiting time of 175 days with only 1 patient developing tumor recurrence (2.4%). 15 More recently, a large prospective study investigated the effect of TACE on post-LT survival in 116 patients with 43% of the patients having HCV-related HCC. 16 In this 10-year experience, benefits were seen only in a subgroup of patients whose disease met the Milan criteria, but not in those whose disease exceeded the Milan criteria. Patients exceeding the Milan criteria were also more likely to drop out as a result of tumor progression while waiting for LT (dropout rate, 12.1 vs. 2.9%) and to develop HCC recurrence (dropout rate, 21.6 vs. 7.6%). Additional studies have also suggested a beneficial effect of TACE in those patients on the waiting list for LT, especially when using multimodality approach to treating the HCC. 17, 18 Despite the lack of high level evidence of the clinical benefit of transarterial treatment for HCC on post-LT tumor recurrence and survival, the majority of transplant programs are increasingly performing local-regional treatments for waiting candidates. For example, a review of the Scientific Registry of Transplant Recipients data showed that HCC patients treated with local-regional treatment had improved overall survival rates at 3 years when compared with untreated patients. 19 The available evidence on local-regional treatment for HCC candidates on the waiting list was reviewed in a recent United States National Conference on Liver Allocation. 20 The AFP indicates a-fetoprotein; IFN, interferon; LT, liver transplantation; NTT, no pre-LT transarterial treatment; PTT, pre-LT transarterial therapy. general consensus recommendations from this meeting were that the use of local-regional treatments in HCC are strongly encouraged.
The failure of transarterial therapy to impact post-LT survival and the recurrence rate in our study is likely multifaceted. The observed trend toward a higher rate of recurrence in the PTT group versus NTT group may be related to the small number of patients in the treatment group and the vulnerability of this outcome to a small number of events. In other studies, the number of transarterial treatments within the waiting time showed a benefit with TACE applied for an average of 3 to 4.5 courses of treatment. 21 The variation of the waiting time across the studies may also explain the differences in outcomes. Regional variation in time to LT is a significant variable with the potential to influence dropout from tumor progression, HCC recurrence rate and post-LT survival. In our series, the majority of the patients were transplanted within 3 months and this short waiting time may not have been long enough to capture the benefit of transarterial treatment. The importance of the waiting time or a treat and wait observational period has been proposed as a selection criteria to expose those HCCs with an unfavorable tumor biology. 22, 23 The shorter waiting time in the PTT group along with the lack of a treat and wait observational strategy may have selected patients in the PTT group with more aggressive tumor biology and negatively impacted the outcome. In addition, the shorter waiting time in the PTT group in our study may not have allowed enough time to maximize the transarterial treatments.
Although the patients in both subgroups (PTT vs. NTT) seemed to be well matched for tumor features and underlying liver disease, the NTT group received significantly more post-LT interferon treatment for HCV than patients in the PTT group. This disparity between the subgroups suggests that interferon exposure may influence tumor recurrence and post-LT survival. The role of interferon in the adjuvant setting to prevent HCC is controversial. The data on adjuvant interferon are limited to single center experiences in the surgical resection literature and the only endpoint that consistently translates into a decreased risk of future HCC recurrence is achieving a sustained virologic response. 24, 25 However, we did not observe significant differences in sustained virologic response and rate of fibrosis progression from HCV recurrence in the allograft to explain the difference in overall survival. In addition, our use of bland embolization as the sole transarterial treatment, instead of chemoembolization, which is the modality used in most studies, may be a reason why we did [26] [27] [28] These findings suggest the potential for such treatments to also modify tumor behavior.
The long-term outcomes of patients with HCV-related HCC receiving or not receiving PTT remain poorly defined because of a paucity of robust data. Our retrospective analysis using transarterial therapy in the form of bland embolization as a management strategy for HCC in the pre-LT setting shows that intervention for those within the Milan criteria transplanted within 3 months does not benefit overall post-LT patient survival. Further, the higher recurrence rate with transarterial treatment compared with no intervention raises concern that local-regional treatments that target arterial supply not only affect the tumor burden but may modify the tumor biology. Although the retrospective design and small number of patients in the study is subject to inherent limitations, the results in our study represent important findings in the area of managing HCC in patients that are on the LT waiting list. The etiology of cirrhosis leading to the genesis of HCC is an important variable that needs to be evaluated in a uniform manner given that HCC is highly heterogeneous with molecular alterations that likely differ based on risk factor. In our study, the impact of transarterial treatment was evaluated in a population of patients with uniform HCC tumor burden (Milan criteria) and similar rates of HCV as the etiology for liver disease.
In conclusion, this case-control study suggests that TAE performed on HCV-related HCC patients while on the waiting list has no benefit on post-LT survival and tumor recurrence. In addition, pre-LT TAE seems to confer a negative impact on long-term post-LT survival at 5 years. Further analyses are needed in this population of patients to determine whether pre-LT intervention may actually harm HCV patients' survival. Prospective randomized studies are needed but feasibility will be problematic as the variation of waiting times is difficult to control.
